ADT combined withabiraterone and prednisone in the treatment of a patient with metastatic hormone-sensitive prostate cancer / 中华泌尿外科杂志

ABSTRACT

Androgen deprivation therapy (ADT) combined with abiraterone and prednisone.for metastatic hormone sensitive prostate cancer (mHSPC) is proved effective in many researches, but it is not verified in china. We present the case of a 62-year-old man who was referred to our hospital for high-risk mHSPC with the main symptoms of dysuria and weak stream. the level of prostate-specific antigen (PSA) was elevated, and the results of biopsy, magnetic resonance and PET-CT showed prostate cancer with multiple lymph node metastases to the right scapula and right pubic bone (T 3bN 1M 1b). The patients were treated with the combination of ADT plus abiraterone and prednisone. After treatment, the level of PSA and testosterone returned to normal and were well-controlled.